LivaNova Appoints New Board Member
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- New Board Member: LivaNova PLC announced the election of Jette Nygaard-Andersen to its Board of Directors during the Annual General Meeting on June 10, bringing extensive governance expertise and leadership skills that are expected to enhance the company's strategic development and innovation.
- Rich Leadership Experience: Nygaard-Andersen has over 25 years of leadership experience in international businesses, having served as Chair of Coloplast A/S and led significant growth transformations at Entain plc, showcasing her strategic value in complex global operations.
- Board Changes: Concurrent with Nygaard-Andersen's appointment, Sharon O'Kane decided not to seek re-election, concluding over a decade of service on LivaNova's board, which introduces new dynamics to the governance structure and may influence future decision-making.
- Governance Structure Optimization: Brooke Story will succeed O'Kane as Chair of the Nominating and Corporate Governance Committee, with new committee members working alongside Nygaard-Andersen to enhance board diversity and expertise, supporting the company's ongoing growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LIVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LIVN
Wall Street analysts forecast LIVN stock price to fall
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 78.380
Low
64.00
Averages
72.50
High
85.00
Current: 78.380
Low
64.00
Averages
72.50
High
85.00
About LIVN
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LivaNova Appoints New Board Member
- New Board Member: LivaNova PLC announced the election of Jette Nygaard-Andersen to its Board of Directors during the Annual General Meeting on June 10, bringing extensive governance expertise and leadership skills that are expected to enhance the company's strategic development and innovation.
- Rich Leadership Experience: Nygaard-Andersen has over 25 years of leadership experience in international businesses, having served as Chair of Coloplast A/S and led significant growth transformations at Entain plc, showcasing her strategic value in complex global operations.
- Board Changes: Concurrent with Nygaard-Andersen's appointment, Sharon O'Kane decided not to seek re-election, concluding over a decade of service on LivaNova's board, which introduces new dynamics to the governance structure and may influence future decision-making.
- Governance Structure Optimization: Brooke Story will succeed O'Kane as Chair of the Nominating and Corporate Governance Committee, with new committee members working alongside Nygaard-Andersen to enhance board diversity and expertise, supporting the company's ongoing growth.
See More
LivaNova Appoints New Chief Legal Officer
- Executive Appointment: LivaNova PLC announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31, overseeing the company's global legal and compliance functions while joining the Executive Leadership Team, highlighting the company's commitment to legal compliance.
- Extensive Experience: Liddy brings over two decades of legal expertise, having served as General Counsel at Hologic where she led a global legal organization and advised senior leadership and the Board on critical business and compliance matters, which is expected to enhance LivaNova's strategic leadership.
- Strategic Impact: Liddy expressed her intention to collaborate with the leadership team to support the company's strategic priorities and advance its global compliance framework, aiming to improve patient lives through innovation and create long-term value for customers and shareholders.
- Educational Background: Liddy holds a Bachelor of Arts degree from the College of the Holy Cross and a Juris Doctor from Cornell University Law School, and her educational and professional background will provide robust support for LivaNova's legal affairs.
See More
LivaNova Appoints New President of Cardiopulmonary Division
- Leadership Transition: LivaNova PLC announced that Stefano Folli will succeed Franco Poletti as President of Cardiopulmonary effective June 1, ensuring a smooth leadership transition that is expected to enhance the company's strategic execution in the cardiopulmonary medical technology sector.
- Business Scale: Folli will oversee a nearly $800 million cardiopulmonary business, including the Essenz™ Perfusion System, and is anticipated to drive growth and innovation through his extensive industry experience.
- Experience Background: Folli's previous role as Global President of Ambulatory Monitoring & Diagnostics at Philips involved successful integration of acquisitions and strengthening market leadership, showcasing his deep expertise and leadership capabilities that will bring new perspectives and strategies to LivaNova.
- Strategic Vision: Folli expressed his commitment to collaborating with the global team to enhance execution and innovation, aiming to improve outcomes for patients and clinicians, which underscores LivaNova's long-term dedication to the medical technology field.
See More
LivaNova (LIVN) Q1 2025 Earnings Transcript
See More
LIVANOVA: BARCLAYS INCREASES TARGET PRICE TO $76, UP FROM $73
- Company Update: Livanova has raised its target price to $76 from $73.
- Market Reaction: The adjustment reflects positive market sentiment towards Livanova's performance and future prospects.
See More
LivaNova Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: LivaNova achieved an 11% revenue growth in Q1 2026, reaching $362 million, demonstrating strong performance in its cardiopulmonary and epilepsy segments, which enhances the company's competitive position in the medical device market.
- Optimistic Market Outlook: The company now expects cardiopulmonary revenue growth for 2026 to rise to 8.5%-9.5% and epilepsy growth to 6%-7%, reflecting management's confidence in future market demand.
- FDA Approval of New Device: LivaNova received FDA premarket approval for the aura6000 system, the first hypoglossal nerve stimulation device approved without complete consent, marking a strategic entry into the obstructive sleep apnea market.
- Cash Flow and Investment: The adjusted free cash flow for Q1 was $4 million, while capital expenditures were $14 million, primarily driven by cardiopulmonary capacity expansion and next-generation oxygenator manufacturing upgrades, indicating the company's commitment to ongoing investments for future growth.
See More
LivaNova Appoints New Board Member
- New Board Member: LivaNova PLC announced the election of Jette Nygaard-Andersen to its Board of Directors during the Annual General Meeting on June 10, bringing extensive governance expertise and leadership skills that are expected to enhance the company's strategic development and innovation.
- Rich Leadership Experience: Nygaard-Andersen has over 25 years of leadership experience in international businesses, having served as Chair of Coloplast A/S and led significant growth transformations at Entain plc, showcasing her strategic value in complex global operations.
- Board Changes: Concurrent with Nygaard-Andersen's appointment, Sharon O'Kane decided not to seek re-election, concluding over a decade of service on LivaNova's board, which introduces new dynamics to the governance structure and may influence future decision-making.
- Governance Structure Optimization: Brooke Story will succeed O'Kane as Chair of the Nominating and Corporate Governance Committee, with new committee members working alongside Nygaard-Andersen to enhance board diversity and expertise, supporting the company's ongoing growth.
See More
LivaNova Appoints New Chief Legal Officer
- Executive Appointment: LivaNova PLC announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31, overseeing the company's global legal and compliance functions while joining the Executive Leadership Team, highlighting the company's commitment to legal compliance.
- Extensive Experience: Liddy brings over two decades of legal expertise, having served as General Counsel at Hologic where she led a global legal organization and advised senior leadership and the Board on critical business and compliance matters, which is expected to enhance LivaNova's strategic leadership.
- Strategic Impact: Liddy expressed her intention to collaborate with the leadership team to support the company's strategic priorities and advance its global compliance framework, aiming to improve patient lives through innovation and create long-term value for customers and shareholders.
- Educational Background: Liddy holds a Bachelor of Arts degree from the College of the Holy Cross and a Juris Doctor from Cornell University Law School, and her educational and professional background will provide robust support for LivaNova's legal affairs.
See More
LivaNova Appoints New President of Cardiopulmonary Division
- Leadership Transition: LivaNova PLC announced that Stefano Folli will succeed Franco Poletti as President of Cardiopulmonary effective June 1, ensuring a smooth leadership transition that is expected to enhance the company's strategic execution in the cardiopulmonary medical technology sector.
- Business Scale: Folli will oversee a nearly $800 million cardiopulmonary business, including the Essenz™ Perfusion System, and is anticipated to drive growth and innovation through his extensive industry experience.
- Experience Background: Folli's previous role as Global President of Ambulatory Monitoring & Diagnostics at Philips involved successful integration of acquisitions and strengthening market leadership, showcasing his deep expertise and leadership capabilities that will bring new perspectives and strategies to LivaNova.
- Strategic Vision: Folli expressed his commitment to collaborating with the global team to enhance execution and innovation, aiming to improve outcomes for patients and clinicians, which underscores LivaNova's long-term dedication to the medical technology field.
See More
LivaNova (LIVN) Q1 2025 Earnings Transcript
See More
LIVANOVA: BARCLAYS INCREASES TARGET PRICE TO $76, UP FROM $73
- Company Update: Livanova has raised its target price to $76 from $73.
- Market Reaction: The adjustment reflects positive market sentiment towards Livanova's performance and future prospects.
See More
LivaNova Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: LivaNova achieved an 11% revenue growth in Q1 2026, reaching $362 million, demonstrating strong performance in its cardiopulmonary and epilepsy segments, which enhances the company's competitive position in the medical device market.
- Optimistic Market Outlook: The company now expects cardiopulmonary revenue growth for 2026 to rise to 8.5%-9.5% and epilepsy growth to 6%-7%, reflecting management's confidence in future market demand.
- FDA Approval of New Device: LivaNova received FDA premarket approval for the aura6000 system, the first hypoglossal nerve stimulation device approved without complete consent, marking a strategic entry into the obstructive sleep apnea market.
- Cash Flow and Investment: The adjusted free cash flow for Q1 was $4 million, while capital expenditures were $14 million, primarily driven by cardiopulmonary capacity expansion and next-generation oxygenator manufacturing upgrades, indicating the company's commitment to ongoing investments for future growth.
See More
